Regulatory Q&A Forum
Ask questions, share knowledge, and get help from the regulatory community
As European authorities advance the proposal to restrict Per- and Polyfluoroalkyl Substances (PFAS) under REACH, how should a non-EU manufacturer, particularly one producing complex articles like medi...
With the European Chemicals Agency (ECHA) expected to advance its opinion on a broad PFAS restriction, non-EU manufacturers face significant challenges in maintaining market access. For companies whos...
While the cost of retaining a REACH Only Representative (OR) can vary significantly, what are the key factors that non-EU manufacturers should evaluate to understand the potential scope and cost of th...
With the 2026 implementation of new French VAT e-invoicing and e-reporting mandates, and the corresponding elimination of certain import mechanisms like Regime 42, many non-EU businesses will be requi...
When developing a novel pharmacogenetic assessment system, which generally falls under regulations like 21 CFR § 862.3364, what is a comprehensive strategy for proactively identifying and addressing t...
When preparing a premarket submission for a connected medical device, such as a networked cardiac monitor, what are the key components of cybersecurity documentation that the FDA generally expects to ...
When a non-U.S. medical device manufacturer plans to enter the U.S. market, appointing a U.S. Agent is a mandatory regulatory requirement. However, the role and value of a U.S. Agent can vary signific...
For manufacturers of electronic medical devices, navigating international markets involves more than just clinical and performance data for regulatory clearance; it also includes complex, region-speci...
For medical device manufacturers placing products on the market in jurisdictions with Extended Producer Responsibility (EPR) and Waste Electrical and Electronic Equipment (WEEE) regulations, appointin...
As the EU's Waste from Electrical and Electronic Equipment (WEEE) Directive and Extended Producer Responsibility (EPR) frameworks evolve, with significant revisions anticipated around 2026, how should...
For manufacturers of electronic medical devices, appointing a WEEE (Waste Electrical and Electronic Equipment) and EPR (Extended Producer Responsibility) representative is a critical step for market a...
With international consensus standards for biocompatibility undergoing periodic updates, how can manufacturers strategically assess the impact of these changes on both new and existing medical devices...
With international consensus standards for biocompatibility undergoing periodic and significant updates, how should manufacturers strategically re-evaluate their biological safety approach for existin...
Determining the required biocompatibility testing for an FDA 510(k) submission is not a fixed checklist but a risk-based process tailored to the specific medical device. How can sponsors construct a r...
Given industry discussions around a potential new global biocompatibility standard emerging by 2026, how can medical device manufacturers proactively prepare their strategies and documentation to avoi...
With the European Chemicals Agency (ECHA) moving towards significant restrictions on per- and polyfluoroalkyl substances (PFAS) under REACH, non-EU manufacturers face a critical compliance challenge. ...
Given the increasing regulatory focus on per- and polyfluoroalkyl substances (PFAS) under REACH, particularly with the development of a universal restriction proposal, how should a non-EU manufacturer...
What factors determine the scope of services and responsibilities for a REACH Only Representative? For non-EU manufacturers of chemical substances, appointing a REACH Only Representative (OR) is a cr...
For a sponsor developing a novel, complex Software as a Medical Device (SaMD) intended for pharmacogenetic assessment, what are the key intersecting regulatory requirements that must be addressed in a...
For non-EU medical device manufacturers, selecting an EU Authorized Representative (AR) under the Medical Device Regulation (MDR) is a critical compliance decision that extends far beyond a simple adm...